Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TECHNOLOGY REIMBURSEMENT PROPOSALS TO PRIVATE PAYERS SHOULD INCLUDE PATIENT SELECTION CRITERIA, BLUES PLAN EXEC SAYS; SIDE-BY-SIDE COMPARISONS ALSO SOUGHT

This article was originally published in The Gray Sheet

Executive Summary

Manufacturers seeking reimbursement from private payers for new technologies should identify the subset of patients for which the device demonstrates the greatest clinical value, Grant Lawless, MD, VP-medical and pharmacy affairs for the Pennsylvania-based Highmark Blue Cross/Blue Shield Plan said Feb. 4 at a meeting in New York City.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009603

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel